ArticleOncoimmunology2013

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.

Vidyalakshmi Chandramohan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.